Alzamend Neuro (9ZT) Financial Statements
Alzamend Neuro Financial Overview
Alzamend Neuro's market cap is currently $5.21M. The company's EPS TTM is $-2.30; its P/E ratio is -0.53; Alzamend Neuro has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Apr 26 | Apr 25 | Apr 24 | Apr 23 | Apr 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -8.77M | $ -4.50M | $ -9.94M | $ -14.87M | $ -12.32M |
| EBITDA | $ -8.66M | $ -4.45M | $ -9.89M | $ -14.85M | $ -12.31M |
| Net Income | $ -8.77M | $ -4.51M | $ -9.95M | $ -14.88M | $ -12.36M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 710.69K | $ 3.95M | $ 376.05K | $ 5.14M | $ 14.06M |
| Total Assets | $ 2.08M | $ 4.60M | $ 631.59K | $ 5.92M | $ 14.52M |
| Total Debt | $ 0.00 | $ 0.00 | $ 300.71K | $ 0.00 | $ 0.00 |
| Net Debt | $ -710.69K | $ -3.95M | $ -75.33K | $ -5.14M | $ -14.06M |
| Total Liabilities | $ 1.35M | $ 634.76K | $ 3.23M | $ 2.87M | $ 1.16M |
| Stockholders' Equity | $ 733.21K | $ 3.97M | $ -2.59M | $ 3.05M | $ 13.35M |
| Cash Flow | |||||
| Free Cash Flow | $ -8.07M | $ -6.87M | $ -8.42M | $ -8.92M | $ -6.72M |
| Operating Cash Flow | $ -8.07M | $ -6.57M | $ -8.27M | $ -8.92M | $ -6.61M |
| Investing Cash Flow | $ 0.00 | $ -300.00K | $ -147.24K | $ 0.00 | $ -106.46K |
| Financing Cash Flow | $ 4.83M | $ 10.44M | $ 3.65M | $ 200.00 | $ 18.85M |
Currency in USD